PROSPECTUS                                    Filed Pursuant to Rule 424 (b) (3)
                                                     Registration No. 333-139082

                                 500,000 SHARES

                             SIGA TECHNOLOGIES, INC.

                                  COMMON STOCK

                                   ----------

      Shares of common stock of SIGA  Technologies,  Inc.  are being  offered by
this  prospectus.  The  shares  will be sold  from  time to time by the  selling
stockholders  named  in this  prospectus.  The  prices  at  which  such  selling
stockholders  may sell the shares will be  determined by the  prevailing  market
price for the shares or in  negotiated  transactions.  We will not  receive  any
proceeds  from the sale of shares of common  stock by the selling  stockholders.
Our shares are traded on the NASDAQ  Capital Market under the symbol "SIGA." Our
principal executive offices are located at 420 Lexington Avenue,  Suite 408, New
York, New York 10170. Our telephone number is (212) 672-9100.

                                   ----------

      Investing  in the  shares  involves  a  high  degree  of  risk.  For  more
information, please see "Risk Factors" beginning on page 6.

                                   ----------

      Neither the  Securities and Exchange  Commission nor any state  securities
commission has approved or disapproved of these securities or determined if this
prospectus  is truthful or  complete.  Any  representation  to the contrary is a
criminal offense.

                                   ----------

                The date of this prospectus is December 26, 2006



                                TABLE OF CONTENTS

ABOUT SIGA TECHNOLOGIES, INC...................................................1

RISK FACTORS...................................................................6

ABOUT THIS PROSPECTUS.........................................................14

FORWARD-LOOKING STATEMENTS....................................................14

USE OF PROCEEDS...............................................................15

SELLING STOCKHOLDERS..........................................................16

PLAN OF DISTRIBUTION..........................................................16

LEGAL MATTERS.................................................................18

EXPERTS.......................................................................18

COMMISSION'S POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES.......18

ADDITIONAL INFORMATION........................................................18

INCORPORATION BY REFERENCE....................................................19



                          ABOUT SIGA TECHNOLOGIES, INC.

      We are a  biotechnology  company  incorporated  in Delaware on December 9,
1996.  We aim to  discover,  develop and  commercialize  novel  anti-infectives,
antibiotics and vaccines for serious infectious diseases, including products for
use  in  defense  against   biological  warfare  agents  such  as  smallpox  and
arenaviruses (hemorrhagic fevers). Our lead product under development, SIGA-246,
is an orally  administered  anti-viral  drug that targets the smallpox virus. In
December 2005, the FDA accepted our IND application for SIGA-246 and granted the
program  "Fast-Track"  status.  Fast Track  programs of the FDA are  designed to
facilitate  the  development  and  expedite  the  review of new  drugs  that are
intended to treat serious or  life-threatening  conditions and that  demonstrate
the  potential to address  unmet  medical  needs.  Our  anti-viral  programs are
designed  to  prevent  or limit  the  replication  of the  viral  pathogen.  Our
anti-infectives  programs are aimed at the increasingly  serious problem of drug
resistance. We are also working to develop a technology for the mucosal delivery
of our vaccines  which may allow the  vaccines to activate the immune  system at
the mucus lined  surfaces of the body -- the mouth,  the nose, the lungs and the
gastrointestinal and urogenital tracts -- the sites of entry for most infectious
agents.

                     Product Candidates and Market Potential

                SIGA Biological Warfare Defense Product Portfolio

      Anti-Smallpox  Drug: Smallpox virus is classified as a Category A agent by
the Center for Disease  Control and Prevention  ("CDC") and is considered one of
the most  significant  threats for use as a biowarfare  agent.  While deliberate
introduction of any pathogenic  agent would be  devastating,  we believe the one
that has greatest potential to harm the general U.S. population is smallpox.  At
present  there is no  effective  drug with  which to treat or  prevent  smallpox
infections. To address this serious risk, SIGA scientists have identified a lead
drug  candidate,   SIGA-246,   which  inhibits  vaccinia,   cowpox,   ectromelia
(mousepox), monkeypox, camelpox, and variola replication in cell culture but not
other unrelated  viruses.  There might be several uses for an effective smallpox
antiviral drug:  prophylactically,  to protect the non-immune who are at risk to
exposure;  therapeutically,  to  prevent  disease  or death in those  exposed to
smallpox;  and last,  as an adjunct  treatment  to the  immunocompromised.  SIGA
scientists  are also working on several other  smallpox drug targets,  including
the  viral  proteinases,  to  develop  additional  drug  candidates  for  use in
combination  therapy if necessary.  In December  2005,  the FDA approved our IND
application  for SIGA-246.  We initiated a Phase I clinical  trial in the second
quarter of 2006. The Phase I human trials were  performed at Advance  Biomedical
Research, Inc.'s clinical unit in Hackensack,  New Jersey. The primary objective
of the  initial  study was to  evaluate  the safety and  tolerability  of single
escalating  doses  of  SIGA-246  in  healthy  volunteers.   In  2005,  the  drug
demonstrated  antiviral  activity in various animal models of poxvirus  disease,
including the complete  protection of golden ground  squirrels from lethal doses
of monkeypox  virus.  In October,  2006, we reported that the drug  demonstrated
100% protection against human smallpox virus in a primate trial conducted at the
federal Centers for Disease Control and Prevention.  Further,  in November 2006,
we reported that the drug also demonstrated  protection  against monkeypox virus
in a primate trial.

      Anti-Arenavirus Drug: Arenaviruses are hemorrhagic fever viruses that have
been  classified as Category A agents by the CDC due to the great risk that they
pose to  public  health  and  national  safety.  Among  the  Category  A viruses
recognized by the CDC, there are four New World hemorrhagic  fever  arenaviruses
(Junin,  Machupo,  Guanarito  and  Sabia  viruses)  for  which  there are no FDA
approved  treatments  available.  In order to meet this threat,  SIGA scientists
have identified a lead drug candidate,  ST-294, which has demonstrated antiviral
activity in cell culture  assays  against  arenavirus  pathogens.  SIGA also has
earlier stage programs in development  against other  hemorrhagic fever viruses,
including Lassa virus,  Lymphocytic  choriomeningitis virus ("LCMV"), and Ebola.
We believe that the  availability  of hemorrhagic  fever virus  antiviral  drugs
could address  national and global  security  needs by acting as a deterrent and
defense against the use of arenaviruses as weapons of bioterrorism.


                                       1


Bacterial  Commensal  Vectors:  Our scientists have developed methods that allow
essentially  any gene  sequence to be expressed  in  Generally  Regarded As Safe
("GRAS") gram-positive bacteria, with the foreign protein being displayed on the
surface of the live  recombinant  organisms.  Since organisms are inexpensive to
grow and are very stable,  this  technology  affords the  possibility of rapidly
producing live  recombinant  vaccines  against any variety of biological  agents
that might be encountered,  such as Bacillus anthracis  ("anthrax") or smallpox.
SIGA  scientists  are working to develop an  alternative  vaccine with  improved
safety for use in preventing human disease caused by pathogenic  orthopoxviruses
such  as  variola  virus.   To  accomplish   this  goal  we  are  utilizing  our
newly-developed  BCV  (bacterial  commensal  vector)  technology.  BCV  utilizes
gram-positive   commensal  bacteria,   such  as  Streptococcus   gordonii,  ("S.
Gordonii") to express heterologous antigens of interest, either in secreted form
or attached to its external surface. Phase I human clinical trials indicate that
this S.  Gordonii  strain  is safe and  well-tolerated  in  humans.  In  several
different  animal  model  systems,  S.  Gordonii  has been shown to  efficiently
express  various  antigens and elicit  protective  immune  responses  (cellular,
humoral  and  mucosal).  However,  these  trials are not a  predictor  of future
success.

      Surface  Protein  Expression  ("SPEX/PLEX")  System:  Our scientists  have
harnessed the protein expression  pathways of gram-positive  bacteria and turned
them into  protein  production  factories.  Using our  proprietary  SPEX or PLEX
systems,  we can produce  foreign  proteins at high levels in the laboratory for
use  in  subunit  vaccine   formulations  or  other  therapeutic   applications.
Furthermore,  we can envision engineering these bacteria to colonize the mucosal
surfaces of soldiers and/or civilians and secrete therapeutic  molecules -- e.g.
anti-toxins that protect against aerosolized botulism toxin.

      Antibiotics:  To combat the problems  associated with emerging  antibiotic
resistance, our scientists are developing drugs designed to address a new target
-- the  bacterial  adhesion  organelles.  Specifically,  by using novel  enzymes
required for the transport  and/or  assembly of the proteins and structures that
bacteria require for adhesion or colonization,  we are developing new classes of
broad spectrum antibiotics.  This may prove useful in providing prompt treatment
to individuals  encountering  an unknown  bacterial  pathogen in the air or food
supply.

                     Market for Biological Defense Programs.

      The Department of Homeland Security ("DHS")  appropriation  bill signed by
President  Bush on  October  1, 2003  created a  discretionary  reserve  of $5.6
billion   to   fund   Project    BioShield    for   a   period   of   10   years
(www.aamc.org/advocacy/library/laborhhs/labor0022.htm).   $3.4  billion  may  be
obligated  during the first 5 years of the bill,  and was included in the United
States     government's     budgets     for     fiscal     2004     and     2005
(www.whitehouse.gov/omb/budget/fy2006/tables.html).  The  remainder  is reserved
for the last 5 years of the bill.  Project BioShield was introduced to encourage
pharmaceutical   and   biotechnology    companies   to   develop    bioterrorism
countermeasures.  One of the major  concerns in the field of biological  warfare
agents is  smallpox  -- although  declared  extinct in 1980 by the World  Health
Organization ("WHO"), there is a threat that a rogue nation or a terrorist group
may have an illegal inventory of the virus that causes smallpox. It is generally
believed that the only legal  inventories of the virus are held under  extremely
tight security at the CDC in Atlanta,  Georgia and at a laboratory in Russia. As
a result  of this  threat,  the U.S.  government  has  announced  its  intent to
allocate  significant  expenditures  to find a way to  counteract  the  virus if
turned loose by terrorists or on a battlefield.

Although enough smallpox vaccine exists to vaccinate the entire U.S. population,
a number of issues exist.  There is no proven safe and  effective  treatment for
smallpox.  According  to the  Center  for  Disease  Control,  vaccination  after
exposure to the smallpox virus offers some benefit;  however,  after 7 days post
exposure, the benefit is significantly limited. In addition, side effects can be
serious in approximately  1,000 out of every million people receiving a smallpox
vaccination.  Up to 52 people out of every million  vaccinated would be expected
to  experience  life  threatening  reactions,  with 1 to 2  people  per  million
expected to die. Importantly,  existing smallpox vaccines are contraindicated in
immunosupressed  individuals  and in  individuals  with  immunosupressed  family
members. This  contraindication  translates into approximately 30 percent of the
U.S.  population that cannot be vaccinated  against  smallpox  without taking on
significant


                                       2


health risks.  There are two medications  that may help persons who have adverse
reactions to the  vaccination:  vaccinia  immune  globulin  (VIG) and cidofovir.
Although used extensively in the past, VIG has been shown in controlled  studies
to not be effective.  The antiviral drug,  cidofovir,  licensed for treatment of
CMV retinitis has  demonstrated  activity  against pox viruses.  It is currently
available  under  treatment  IND in the event of adverse  reactions  to smallpox
vaccine where VIG is not efficacious.

      The FDA amended its regulations,  effective June 30, 2002, so that certain
new drug and  biological  products  used to reduce or prevent  the  toxicity  of
chemical,  biological,  radiological,  or nuclear substances may be approved for
use in humans based on evidence of  effectiveness  derived only from appropriate
animal studies and any additional  supporting  data. We believe that this change
could make it possible for us to have our  products  which have been found to be
effective in animal  studies to be approved  for sale within a relatively  short
time.

                       SIGA Antibiotics Product Portfolio

      Our  anti-infectives  program is targeted  principally  at  drug-resistant
bacteria and hospital-acquired infections.  According to estimates from the CDC,
approximately  two million  hospital-acquired  infections occur each year in the
United  States.  Our  anti-infectives  approaches  aim to block the  ability  of
bacteria to attach to and colonize human tissue,  thereby blocking  infection at
the first stage in the infection process. By comparison,  antibiotics  available
today act by  interfering  with  either the  structure  or the  metabolism  of a
bacterial cell, affecting its ability to survive and to reproduce.  No currently
available antibiotics target the attachment of a bacterium to its target tissue.
We believe that by preventing attachment, the bacteria should be readily cleared
by the body's immune system.  SIGA has  Gram-positive,  Gram-negative  and broad
spectrum antibiotic technologies.

                        SIGA Antivirals Product Portfolio

      SIGA currently has the following  antiviral  programs which are in various
stages of development, ranging from initial research and screening to initiation
of Phase I human  clinical  trials:  smallpox  antiviral,  New World  Arenavirus
antiviral,   Old  World  Arenavirus  antiviral,   Filovirus  (Ebola  &  Marburg)
antivirals,  Dengue Fever virus antiviral, and Bunyavirus antivirals.  Currently
there are no approved antivirals available against any of these viruses.

                       Market for Anti-infective Programs

      There are currently  approximately  83 million  prescriptions  written for
antibiotics annually in the U.S  (www.iatrogenic.org/library/antibioticlib.html)
and it is  estimated  that  the  worldwide  market  for  antibiotics  was  worth
approximately $23.7 billion in 2004  (www.pharmaprojectsplus.com).  Although our
products are too early in development  to make accurate  assessments of how well
they might  compete,  if  successfully  developed  and  marketed  against  other
products  currently  existing or in  development  at this time,  the  successful
capture of even a  relatively  small  global  market share could lead to a large
dollar volume of sales.  Some of the antivirals  that SIGA is developing are for
biowarfare  agents and the market for that area is currently  unknown;  however,
there is funding  available to purchase these drugs in Project Bioshield as well
as through the DoD. Markets for the other antiviral programs at SIGA vary widely
depending on the virus and where they are endemic.  Each of these  programs will
be assessed on an  individual  basis as it approaches  the New Drug  Application
stage.

                                   Technology

      Antiviral  Technology-Two  Approaches:  SIGA  has  two  approaches  to the
discovery and development of new antiviral  compounds:  rational drug design and
high-throughput  screening  ("HTS").  For  rational  drug  design,  SIGA applies
advanced  receptor  structure-based  Virtual  Ligand  Screening  technology  for
ligand/inhibitor  discovery.  The analysis of the structure reveals  potentially
"drugable" pockets. The


                                       3


technology  allows us to utilize the  three-dimensional  structure of the target
receptor to screen large virtual compound  collections,  as well as databases of
commercially   available   compounds,   and   prioritize   them  for  subsequent
experimental validation.  Rational drug design is also used to develop structure
activity relationships and lead optimization.

      For HTS, SIGA uses whole cell virus  inhibition  assays,  pseudotype virus
inhibition  assays,  as  well  as  validated  target  biochemical  assays.  SIGA
currently has an in-house compound library consisting of 200,000 small molecules
that is utilized for screening in these various assays. This strategy allows for
both target specific and target neutral  screening and  identification  of novel
antiviral  compounds.  Compounds  are also screened for toxicity in various cell
lines to develop a therapeutic index ("TI"), which is the concentration that the
compound is toxic to 50% of the cells  (CC50)  divided by the  concentration  of
compound required to inhibit 50% of the virus (EC50)  (TI=CC50/EC50).  Once hits
are   identified   with  an  acceptable  TI,  they  are  selected  for  chemical
optimization and proceed in to the antiviral drug development pipeline.

           Vaccine Technologies: Mucosal Immunity and Vaccine Delivery

      Using  proprietary   technology   licensed  from  Rockefeller   University
(Rockefeller),  SIGA is developing specific commensal bacteria ("commensals") as
a means to deliver  mucosal  vaccines.  Commensals  are harmless  bacteria  that
naturally  occupy the  body's  surfaces  with  different  commensals  inhabiting
different  surfaces,  particularly the mucosal surfaces.  Our vaccine candidates
use  genetically  engineered  commensals  to deliver  antigens  for a variety of
pathogens to the mucosal  immune  system.  When  administered,  the  genetically
engineered commensals colonize the mucosal surface and replicate.  By activating
a local mucosal immune response,  our vaccine candidates are designed to prevent
infection  and  disease  at the  earliest  possible  stage,  as  opposed to most
conventional  vaccines  which are  designed to act after  infection  has already
occurred.

      By using  an  antigen  unique  to a given  pathogen,  the  technology  may
potentially  be applied to any  infectious  agent that enters the body through a
mucosal  surface.  Our scientists have expressed and anchored a variety of viral
and bacterial  antigens on the outside of S. Gordonii,  including the M6 protein
from  group A  streptococcus,  a group  of  organisms  that  causes  a range  of
diseases,  including strep throat,  necrotizing fasciitis,  impetigo and scarlet
fever. In addition, proteins from other infectious agents, such as HIV and human
papilloma  virus,  have also been expressed  using this system.  We believe this
technology  will enable the  expression of most  antigens  regardless of size or
shape. In animal studies, we have found that the administration of a genetically
engineered S. Gordonii  vaccine  prototype  induces both a local mucosal  immune
response and a systemic immune response.

              Surface Protein Expression Systems ("SPEX" & "PLEX")

      The ability to overproduce many bacterial and human proteins has been made
possible through the use of recombinant DNA technology.  The introduction of DNA
molecules  into  Escherichia  coli ("E.  coli") has been the method of choice to
express  a  variety  of  gene  products,   because  of  this  bacterium's  rapid
reproduction and well-understood  genetics. Yet, despite the development of many
efficient E.  coli-based  gene expression  systems,  the most important  concern
continues  to  be  associated  with  subsequent  purification  of  the  product.
Recombinant  proteins  produced in this  manner do not  readily  cross E. coli's
outer  membrane,  and as a result,  proteins must be purified from the bacterial
cytoplasm or  periplasmic  space.  Purification  of proteins from these cellular
compartments can be very difficult.  Frequently encountered problems include low
product yields,  contamination  with potentially  toxic cellular material (i.e.,
endotoxin)  and the formation of large amounts of partially  folded  polypeptide
chains in non-active aggregates termed inclusion bodies.

To  overcome  these  problems,  we have  taken  advantage  of our  knowledge  of
Gram-positive  bacterial protein expression and anchoring pathways. This pathway
has  evolved to handle the  transport  of surface  proteins  that vary widely in
size, structure and function. Modifying the approach used to create bacterial


                                       4


commensal  mucosal  vaccines,  we  have  developed  methods  which,  instead  of
anchoring the foreign  protein to the surface of the  recombinant  Gram-positive
bacteria,  result in it being secreted into the  surrounding  medium in a manner
which  is  readily  amenable  to  simple  batch  purification.  We  believe  the
advantages  of this  approach  include the ease and lower cost of  Gram-positive
bacterial  growth,  the likelihood  that secreted  recombinant  proteins will be
folded properly, and the ability to purify recombinant proteins from the culture
medium  without having to disrupt the bacterial  cells and  liberating  cellular
contaminants.  Gram-positive  bacteria  may be grown simply in scales from those
required  for  laboratory  research up to  commercial  mass  production.  Recent
developments in the construction of these recombinant  bacteria have resulted in
a plasmid-based expression system ("PLEX"), in which engineered genetic elements
(plasmids)  are cloned into  commensal  bacteria  for protein  production.  This
system  allows for higher  protein  production  levels  than the  original  SPEX
constructs.  In  addition,  the PLEX and SPEX  systems  may be used in  concert,
enabling  greater  flexibility  in protein  secretion  for  purification  or for
surface expression of multiple proteins,  e.g. for  multi-component  combination
vaccines.


                                       5


                                  RISK FACTORS

      Investing  in our common  stock  involves a high  degree of risk,  and you
should be able to bear  losing  your  entire  investment.  You should  carefully
consider the risks presented by the following factors.

      This prospectus contains forward-looking  statements and other prospective
information  relating to future  events.  These  forward-looking  statements and
other  information are subject to risks and  uncertainties  that could cause our
actual results to differ  materially  from our  historical  results or currently
anticipated results including the following:

We have  incurred  operating  losses since our inception and expect to incur net
losses and negative cash flow for the foreseeable future.

      We incurred net losses of  approximately  $5.6 million for the nine months
ended September 30, 2006, and $2.3 million,  $9.4 million,  and $5.3 million for
the years ended December 31, 2005, 2004, and 2003, respectively.  As of December
31,  2005,  2004 and 2003,  our  accumulated  deficit  was  approximately  $46.5
million, $44.2 million and $34.8 million, respectively. We expect to continue to
incur significant operating  expenditures.  We will need to generate significant
revenues to achieve and maintain profitability.

      We  cannot  guarantee  that  we  will  achieve  sufficient   revenues  for
profitability.  Even if we do achieve profitability, we cannot guarantee that we
can sustain or increase  profitability  on a  quarterly  or annual  basis in the
future.  If revenues grow slower than we  anticipate,  or if operating  expenses
exceed our  expectations or cannot be adjusted  accordingly,  then our business,
results of operations, financial condition and cash flows will be materially and
adversely  affected.  Because our strategy might include  acquisitions  of other
businesses,  acquisition  expenses and any cash used to make these  acquisitions
will reduce our available cash.

Our business will suffer if we are unable to raise additional equity funding.

      We  continue to be  dependent  on our ability to raise money in the equity
markets. There is no guarantee that we will continue to be successful in raising
such funds. If we are unable to raise additional  equity funds, we may be forced
to  discontinue  or cease  certain  operations.  We  currently  have  sufficient
operating capital to finance our operations  beyond the next twelve months.  Our
annual  operating  needs  vary from year to year  depending  upon the  amount of
revenue  generated  through  grants and  licenses  and the amount of projects we
undertake,  as well as the amount of resources  we expend,  in  connection  with
acquisitions  all of  which  may  materially  differ  from  year to year and may
adversely affect our business.

Our stock  price is, and we expect it to remain,  volatile,  which  could  limit
investors' ability to sell stock at a profit.

      The  volatile  price of our stock  makes it  difficult  for  investors  to
predict the value of their  investment,  to sell shares at a profit at any given
time, or to plan purchases and sales in advance. A variety of factors may affect
the market price of our common stock. These include, but are not limited to:

      o     publicity regarding actual or potential clinical results relating to
            products under development by our competitors or us;

      o     delay or failure in initiating, completing or analyzing pre-clinical
            or clinical trials or the unsatisfactory  design or results of these
            trials;

      o     achievement or rejection of regulatory  approvals by our competitors
            or us;

      o     announcements  of   technological   innovations  or  new  commercial
            products by our competitors or us;

      o     developments concerning proprietary rights, including patents;

      o     developments concerning our collaborations;

      o     regulatory developments in the United States and foreign countries;


                                       6


      o     economic or other crises and other external factors;

      o     period-to-period  fluctuations  in our revenues and other results of
            operations;

      o     changes in financial estimates by securities analysts; and

      o     sales and short selling activity of our common stock.

      Additionally,  because there is not a high volume of trading in our stock,
any information about SIGA in the media may result in significant  volatility in
our stock price.

      We will not be able to control many of these factors,  and we believe that
period-to-period  comparisons of our financial  results will not  necessarily be
indicative of our future performance.

      In addition, the stock market in general, and the market for biotechnology
companies in particular,  has experienced  extreme price and volume fluctuations
that may have been unrelated or disproportionate to the operating performance of
individual companies. These broad market and industry factors may seriously harm
the market price of our common stock, regardless of our operating performance.

We are in various stages of product development and there can be no assurance of
successful commercialization.

      In general, our research and development programs are at an early stage of
development.  To obtain FDA approval for our biological warfare defense products
we will be required to perform  two animal  models and provide  animal and human
safety data. Our other products will be subject to the approval guidelines under
FDA  regulatory  requirements  which  include a number of phases of  testing  in
humans.

      The FDA has not approved any of our biopharmaceutical  product candidates.
Any drug candidates developed by us will require significant additional research
and development efforts,  including extensive  pre-clinical and clinical testing
and  regulatory  approval,  prior to  commercial  sale.  We  cannot  be sure our
approach to drug discovery  will be effective or will result in the  development
of any drug.  We cannot  expect that any drugs  resulting  from our research and
development efforts will be commercially available for many years, if at all.

      We have limited experience in conducting pre-clinical testing and clinical
trials. Even if we receive initially positive  pre-clinical or clinical results,
such  results do not mean that  similar  results  will be  obtained in the later
stages of drug  development,  such as additional  pre-clinical  testing or human
clinical trials.  All of our potential drug candidates are prone to the risks of
failure  inherent  in   pharmaceutical   product   development,   including  the
possibility that none of our drug candidates will or can:

o     be safe, non-toxic and effective;

o     otherwise meet applicable regulatory standards;

o     receive the necessary regulatory approvals;

o     develop into commercially viable drugs;

o     be manufactured or produced economically and on a large scale;

o     be successfully marketed;

o     be reimbursed by government and private insurers; and

o     achieve customer acceptance.

      In  addition,  third  parties  may  preclude us from  marketing  our drugs
through  enforcement  of their  proprietary  rights that we are not aware of, or
third parties may succeed in marketing equivalent or superior drug products. Our
failure to develop safe, commercially viable drugs would have a material adverse
effect on our business, financial condition and results of operations.


                                       7


Most of our immediately  foreseeable  future revenues are contingent upon grants
and contracts from the United States  government and  collaborative  and license
agreements and we may not achieve  sufficient  revenues from these agreements to
attain profitability.

      Until and unless we successfully  make a product,  our ability to generate
revenues  will  largely   depend  on  our  ability  to  enter  into   additional
collaborative  agreements,  strategic alliances,  research grants, contracts and
license  agreements  with third parties and maintain the agreements we currently
have in place.  Substantially  all of our revenues for the years ended  December
31, 2005,  2004 and 2003,  respectively,  were derived from revenues  related to
grants, contracts and license agreements. The majority of our current revenue is
derived from  contract  work being  performed for the NIH under two major grants
and a contract,  all of which are  scheduled  to expire in September  2009,  and
contracts with the U.S. Air Force which expire November 2007.  These  agreements
are for specific  work to be performed  under the  agreements  and could only be
canceled  by the  other  party  thereto  for  non-performance.  We may not  earn
significant milestone payments under our existing collaborative agreements until
our collaborators  have advanced  products into clinical testing,  which may not
occur for many years, if at all.

      We have material agreements with the following collaborators:

      o     National  Institutes of Health.  Under our  collaborative  agreement
            with the NIH we have  received  SBIR Grants  totaling  approximately
            $10.8 million in 2006.  The term of these grants expire in September
            2009.  We have also received a three year,  $16.5  million  contract
            from the NIH,  also  expiring in September  2009. We are paid as the
            work  is  performed   and  the   agreement   can  be  cancelled  for
            non-performance. If terminated, we would have to find another source
            of funds to continue  to conduct  the trials.  We are current in all
            our obligations under our agreements.

      o     United States Air Force.  In November 2006 we received two contracts
            from the USAF for a total of $2.3 million.  The contracts  expire in
            November  2007.  We are  current  in all our  obligations  under our
            agreements.

      o     United  States  Army  Medical  Research  and  Material  Command.  In
            September  2005 we entered into a $3.2  million,  one year  contract
            with the USAMRMC.  The agreement,  for the rapid  identification and
            treatment of anti-viral diseases,  is funded through the USAF. It is
            anticipated  that our efforts will aid the USAF  Special  Operations
            Command in its use of  computational  biology to design and  develop
            specific  countermeasures  against biological threat agents Smallpox
            and  Adenovirus.  We are  current in all our  obligations  under our
            agreement.

      o     United  States  Army  Medical  Research  Acquisition   Activity.  In
            December  2002, we entered into a four year contract with USAMRAA to
            develop  a drug  to  treat  Smallpox.  We  are  current  in all  our
            obligations under our agreement.

      o     Rockefeller  University.  The term of our agreement with Rockefeller
            is for the duration of the patents and a number of pending  patents.
            As we do not  currently  know  when any  patents  pending  or future
            patents will expire, we cannot at this time  definitively  determine
            the term of this agreement.  The agreement can be terminated earlier
            if we are in breach of the  provisions  of the  agreement and do not
            cure the breach in the allowed  cure  period.  We are current in all
            obligations under the contract.

      o     Oregon State  University.  OSU is a signatory of our agreement  with
            Rockefeller.  The term of this  agreement is for the duration of the
            patents and a number of pending patents. As we do not currently know
            when any patents pending or future patents will expire, we cannot at
            this time  definitively  determine the term of this  agreement.  The
            agreement  can be  terminated  earlier  if we are in  breach  of the
            provisions  of the  agreement  and do not  cure  the  breach  in the
            allowed cure  period.  We are current in all  obligations  under the
            contract. We have also entered into a subcontract agreement with OSU
            for us to perform work under a grant OSU has from the NIH.


                                       8


            The  subcontract  agreement was  renewable  annually and the current
            terms  expired  on  August  31,  2003.  Work on this  agreement  was
            completed in 2003.

      o     Washington  University.  We have licensed  certain  technology  from
            Washington under a non-exclusive license agreement.  The term of our
            agreement  with  Washington is for the duration of the patents and a
            number of  pending  patents.  As we do not  currently  know when any
            patents  pending or future  patents will  expire,  we cannot at this
            time  definitively  determine  the  term  of  this  agreement.   The
            agreement  cannot be  terminated  unless we fail to pay our share of
            the  joint  patent  costs  for  the  technology  licensed.  We  have
            currently met all our obligations under this agreement.

      o     Regents of the  University of California.  We have licensed  certain
            technology from Regents under an exclusive license agreement. We are
            required  to pay minimum  royalties  under this  agreement.  We have
            currently met all our obligations under this agreement.

      o     TransTech  Pharma,  Inc.  Under  our  collaborative  agreement  with
            TransTech Pharma, a related party, TransTech Pharma is collaborating
            with  us on the  discovery,  optimization  and  development  of lead
            compounds to certain  therapeutic  agents.  We and TransTech  Pharma
            have agreed to share the costs of development and revenues generated
            from licensing and profits from any  commercialized  products sales.
            The agreement  will be in effect until  terminated by the parties or
            upon cessation of research or sales of all products  developed under
            the  agreement.  We  are  current  in  all  obligations  under  this
            agreement.

The  biopharmaceutical  market in which we  compete  and will  compete is highly
competitive.

      The  biopharmaceutical  industry is characterized by rapid and significant
technological  change.  Our  success  will  depend on our ability to develop and
apply our  technologies in the design and development of our product  candidates
and to establish  and maintain a market for our product  candidates.  There also
are many companies, both public and private,  including major pharmaceutical and
chemical  companies,  specialized  biotechnology  firms,  universities and other
research  institutions  engaged in developing  pharmaceutical  and biotechnology
products.   Many  of  these  companies  have  substantially  greater  financial,
technical,  research and development,  and human resources than us.  Competitors
may develop products or other technologies that are more effective than any that
are being  developed by us or may obtain FDA approval for products  more rapidly
than us. If we commence  commercial sales of products,  we still must compete in
the  manufacturing  and  marketing of such  products,  areas in which we have no
experience.  Many of these  companies  also have  manufacturing  facilities  and
established  marketing  capabilities  that would enable such companies to market
competing products through existing channels of distribution. Two companies with
similar profiles are VaxGen, Inc., which is developing vaccines against anthrax,
Smallpox and HIV/AIDS;  and Avant  Immunotherapeutics,  Inc.,  which has vaccine
programs for agents of biological warfare.

Because we must obtain  regulatory  clearance to test and market our products in
the United  States,  we cannot  predict  whether or when we will be permitted to
commercialize our products.

      A  pharmaceutical  product  cannot be  marketed  in the U.S.  until it has
completed  rigorous  pre-clinical  testing and clinical  trials and an extensive
regulatory  clearance process  implemented by the FDA.  Pharmaceutical  products
typically  take many years to satisfy  regulatory  requirements  and require the
expenditure  of  substantial  resources  depending on the type,  complexity  and
novelty of the product.

      Before  commencing  clinical trials in humans,  we must submit and receive
clearance  from  the FDA by means of an IND  application.  Institutional  review
boards and the FDA oversee clinical trials and such trials:

      o     must be  conducted  in  conformance  with the FDA's good  laboratory
            practice regulations;

      o     must meet requirements for institutional review board oversight;


                                       9


      o     must meet requirements for informed consent;

      o     must  meet   requirements   for  good  clinical  and   manufacturing
            practices;

      o     are subject to continuing FDA oversight;

      o     may require large numbers of test subjects; and

      o     may be suspended by us or the FDA at any time if it is believed that
            the  subjects  participating  in these  trials are being  exposed to
            unacceptable  health risks or if the FDA finds  deficiencies  in the
            IND application or the conduct of these trials.

      Before  receiving FDA clearance to market a product,  we must  demonstrate
that the product is safe and  effective on the patient  population  that will be
treated. Data we obtain from preclinical and clinical activities are susceptible
to  varying  interpretations  that  could  delay,  limit or  prevent  regulatory
clearances.  Additionally, we have limited experience in conducting and managing
the clinical trials and manufacturing  processes  necessary to obtain regulatory
clearance.

      If regulatory  clearance of a product is granted,  this  clearance will be
limited  only  to  those  states  and   conditions  for  which  the  product  is
demonstrated  through  clinical  trials  to be safe and  efficacious.  We cannot
ensure that any compound developed by us, alone or with others, will prove to be
safe and  efficacious  in  clinical  trials and will meet all of the  applicable
regulatory requirements needed to receive marketing clearance.

If our  technologies  or  those of our  collaborators  are  alleged  or found to
infringe the patents or proprietary  rights of others, we may be sued or have to
license those rights from others on unfavorable terms.

      Our commercial success will depend significantly on our ability to operate
without  infringing the patents and  proprietary  rights of third  parties.  Our
technologies, along with our licensors' and our collaborators' technologies, may
infringe  the patents or  proprietary  rights of others.  If there is an adverse
outcome  in  litigation  or an  interference  to  determine  priority  or  other
proceeding  in a court or  patent  office,  then we,  or our  collaborators  and
licensors,  could be subjected to significant  liabilities,  required to license
disputed  rights  from or to other  parties  and/or  required  to cease  using a
technology necessary to carry out research,  development and  commercialization.
At present we are unaware of any or potential  infringement  claims  against our
patent portfolio.

      The costs to establish the validity of patents,  to defend  against patent
infringement  claims of others and to assert  infringement claims against others
can be  expensive  and time  consuming,  even if the  outcome is  favorable.  An
outcome of any patent prosecution or litigation that is unfavorable to us or one
of our licensors or  collaborators  may have a material adverse effect on us. We
could incur  substantial  costs if we are required to defend ourselves in patent
suits  brought by third  parties,  if we  participate  in patent  suits  brought
against or initiated by our  licensors or  collaborators  or if we initiate such
suits. We may not have sufficient funds or resources in the event of litigation.
Additionally, we may not prevail in any such action.

      Any conflicts  resulting from third-party patent  applications and patents
could  significantly  reduce the coverage of the patents  owned,  optioned by or
licensed  to us or our  collaborators  and  limit  our  ability  or  that of our
collaborators to obtain meaningful patent  protection.  If patents are issued to
third parties that contain  competitive or conflicting claims, we, our licensors
or our collaborators may be legally  prohibited from researching,  developing or
commercializing of potential products or be required to obtain licenses to these
patents or to develop or obtain alternative technology. We, our licensors and/or
our collaborators may be legally prohibited from using patented technology,  may
not be able to obtain  any  license to the  patents  and  technologies  of third
parties on acceptable  terms, if at all, or may not be able to obtain or develop
alternative technologies.

      In addition,  like many biopharmaceutical  companies,  we may from time to
time hire scientific  personnel formerly employed by other companies involved in
one or more areas similar to the activities


                                       10


conducted by us. We and/or these  individuals  may be subject to  allegations of
trade secret misappropriation or other similar claims as a result of their prior
affiliations.

Our  ability  to  compete  may  decrease  if we do not  adequately  protect  our
intellectual property rights.

      Our commercial  success will depend in part on our and our  collaborators'
ability  to  obtain  and  maintain   patent   protection  for  our   proprietary
technologies,  drug targets and potential  products and to effectively  preserve
our  trade  secrets.  Because  of the  substantial  length  of time and  expense
associated  with  bringing   potential  products  through  the  development  and
regulatory  clearance  processes to reach the  marketplace,  the  pharmaceutical
industry  places  considerable  importance on obtaining  patent and trade secret
protection.  The patent positions of pharmaceutical and biotechnology  companies
can be highly  uncertain  and involve  complex legal and factual  questions.  No
consistent  policy  regarding  the  breadth of claims  allowed in  biotechnology
patents has emerged to date. Accordingly, we cannot predict the type and breadth
of claims allowed in these patents.

      We have licensed the rights to eight issued U.S.  patents and three issued
European  patents.  These patents have varying lives and they are related to the
technology licensed from Rockefeller  University for the Strep and Gram-positive
products.  We  have  one  additional  patent  application  in the  U.S.  and one
application  in Europe  relating  to this  technology.  We are joint  owner with
Washington  University of seven issued patents in the U.S. and one in Europe. In
addition,  there are four co-owned U.S. patent  applications.  These patents are
for the technology used for the Gram-negative product opportunities. We are also
exclusive owner of one U.S. patent and three U.S.  patent  applications.  One of
these U.S. patent applications relates to our DegP product opportunities.

      We included a summary of out patent  positions  as of December 31, 2005 in
Part I, Item 1 of our Annual report on Form 10-K for the year ended December 31,
2005.

      We also rely on copyright protection, trade secrets, know-how,  continuing
technological innovation and licensing  opportunities.  In an effort to maintain
the confidentiality and ownership of trade secrets and proprietary  information,
we  require  our  employees,  consultants  and  some  collaborators  to  execute
confidentiality  and invention  assignment  agreements  upon  commencement  of a
relationship with us. These agreements may not provide meaningful protection for
our  trade  secrets,  confidential  information  or  inventions  in the event of
unauthorized use or disclosure of such  information,  and adequate  remedies may
not exist in the event of such unauthorized use or disclosure.

We may have difficulty managing our growth.

      We expect to  experience  growth in the  number of our  employees  and the
scope of our operations.  This future growth could place a significant strain on
our  management  and  operations.  Our ability to manage this growth will depend
upon our ability to broaden our management team and our ability to attract, hire
and retain skilled employees. Our success will also depend on the ability of our
officers and key employees to continue to implement and improve our  operational
and other systems and to hire, train and manage our employees.

Our activities  involve hazardous  materials and may subject us to environmental
regulatory liabilities.

      Our biopharmaceutical research and development involves the controlled use
of hazardous and radioactive  materials and biological  waste. We are subject to
federal,  state and local laws and regulations  governing the use,  manufacture,
storage,  handling and disposal of these  materials and certain waste  products.
Although we believe that our safety  procedures  for  handling and  disposing of
these materials comply with legally prescribed standards, the risk of accidental
contamination or injury from these materials cannot be completely eliminated. In
the  event of an  accident,  we  could  be held  liable  for  damages,  and this
liability could exceed our resources. The research and development activities of
our  company do not  produce any  unusual  hazardous  products.  We do use small
amounts of 32P, 35S and 3H, which are stored, used and disposed of in accordance
with Nuclear Regulatory Commission ("NRC")


                                       11


regulations.  We maintain  liability  insurance  in the amount of  approximately
$5,000,000  and we believe  this should be  sufficient  to cover any  contingent
losses.

      We  believe  that  we are in  compliance  in all  material  respects  with
applicable  environmental  laws and  regulations  and currently do not expect to
make  material  additional  capital   expenditures  for  environmental   control
facilities in the near term.  However, we may have to incur significant costs to
comply with current or future environmental laws and regulations.

Our potential products may not be acceptable in the market or eligible for third
party  reimbursement  resulting  in a negative  impact on our  future  financial
results.

      Any products  successfully  developed by us or our collaborative  partners
may  not  achieve  market  acceptance.  The  antibiotic  products  which  we are
attempting to develop will compete with a number of well-established traditional
antibiotic drugs  manufactured and marketed by major  pharmaceutical  companies.
The degree of market  acceptance  of any of our products will depend on a number
of factors, including:

      o     the  establishment and demonstration in the medical community of the
            clinical efficacy and safety of such products,

      o     the potential  advantage of such  products  over existing  treatment
            methods, and

      o     reimbursement policies of government and third-party payors.

      Physicians, patients or the medical community in general may not accept or
utilize any products  that we or our  collaborative  partners  may develop.  Our
ability to receive revenues and income with respect to drugs, if any,  developed
through the use of our technology will depend, in part, upon the extent to which
reimbursement  for the cost of such drugs  will be  available  from  third-party
payors,  such as government health  administration  authorities,  private health
care insurers,  health maintenance  organizations,  pharmacy benefits management
companies and other organizations. Third-party payors are increasingly disputing
the prices charged for pharmaceutical products. If third-party reimbursement was
not available or sufficient  to allow  profitable  price levels to be maintained
for drugs  developed by us or our  collaborative  partners,  it could  adversely
affect our business.

If our products harm people, we may experience product liability claims that may
not be covered by insurance.

      We  face an  inherent  business  risk of  exposure  to  potential  product
liability claims in the event that drugs we develop are alleged to cause adverse
effects  on  patients.  Such risk  exists  for  products  being  tested in human
clinical  trials,  as well as products  that  receive  regulatory  approval  for
commercial sale. We may seek to obtain product liability  insurance with respect
to drugs we and/or or our collaborative partners develop. However, we may not be
able to obtain such insurance.  Even if such insurance is obtainable, it may not
be  available  at a  reasonable  cost or in a  sufficient  amount to  protect us
against liability.

We may be required to perform additional  clinical trials or change the labeling
of our products if we or others  identify side effects after our products are on
the market, which could harm sales of the affected products.

      If we or others  identify  side  effects  after any of our products on the
market, or if manufacturing problems occur:

      o     regulatory approval may be withdrawn;

      o     reformulation of our products,  additional clinical trials,  changes
            in labeling of our products may be required;

      o     changes to or  re-approvals of our  manufacturing  facilities may be
            required;


                                       12


      o     sales of the affected products may drop significantly;

      o     our reputation in the marketplace may suffer; and

      o     lawsuits, including class action suits, may be brought against us.

      Any of the above  occurrences  could harm or prevent sales of the affected
products  or could  increase  the  costs and  expenses  of  commercializing  and
marketing these products.

The manufacture of biotechnology  products can be a  time-consuming  and complex
process which may delay or prevent  commercialization  of our  products,  or may
prevent  our  ability  to  produce  an  adequate   volume  for  the   successful
commercialization of our products.

      Our  management  believes  that we have the  ability to acquire or produce
quantities of products  sufficient to support our present needs for research and
our  projected  needs  for  our  initial  clinical  development  programs.   The
manufacture of all of our products will be subject to current Good Manufacturing
Practices (GMP) requirements prescribed by the FDA or other standards prescribed
by the  appropriate  regulatory  agency in the  country of use.  There can be no
assurance  that  we  will be able  to  manufacture  products,  or have  products
manufactured for us, in a timely fashion at acceptable quality and prices,  that
we or third party  manufacturers  can comply with GMP, or that we or third party
manufacturers will be able to manufacture an adequate supply of product.

Healthcare  reform and  controls on  healthcare  spending may limit the price we
charge for any products and the amounts thereof that we can sell.

      The U.S.  federal  government and private insurers have considered ways to
change, and have changed,  the manner in which healthcare  services are provided
in the U.S. Potential approaches and changes in recent years include controls on
healthcare  spending and the creation of large purchasing groups. In the future,
the U.S.  government may institute  further  controls and limits on Medicare and
Medicaid spending.  These controls and limits might affect the payments we could
collect from sales of any products.  Uncertainties  regarding future  healthcare
reform and private market  practices could adversely  affect our ability to sell
any products profitably in the U.S. At present, we do not foresee any changes in
FDA regulatory policies that would adversely affect our development programs.

The future  issuance of preferred  stock may adversely  affect the rights of the
holders of our common stock.

      Our certificate of incorporation allows our Board of Directors to issue up
to  10,000,000  shares  of  preferred  stock  and  to  fix  the  voting  powers,
designations,   preferences,   rights   and   qualifications,   limitations   or
restrictions  of  these  shares  without  any  further  vote  or  action  by the
stockholders.  The rights of the holders of common stock will be subject to, and
could be adversely affected by, the rights of the holders of any preferred stock
that we may  issue  in the  future.  The  issuance  of  preferred  stock,  while
providing  desirable  flexibility in connection with possible  acquisitions  and
other corporate purposes,  could have the effect of making it more difficult for
a third party to acquire a majority of our  outstanding  voting  stock,  thereby
delaying, deferring or preventing a change in control.

Concentration of ownership of our capital stock could delay or prevent change of
control.

      Our directors,  executive officers and principal stockholders beneficially
own a significant  percentage of our common stock and preferred stock. They also
have,  through the exercise or  conversion of certain  securities,  the right to
acquire  additional  common stock. As a result,  these  stockholders,  if acting
together,  have the ability to significantly  influence the outcome of corporate
actions requiring  shareholder  approval.  Additionally,  this  concentration of
ownership  may have the effect of delaying or  preventing a change in control of
SIGA.  At October 31,  2006,  Directors,  Officers  and  principal  stockholders
beneficially owned approximately 49.8% of our stock.


                                       13


                              ABOUT THIS PROSPECTUS

      This prospectus is part of a registration statement that we filed with the
Securities and Exchange Commission.  The prospectus relates to 500,000 shares of
our common stock which may be issued under certain warrant  agreements and which
the selling stockholders named in this prospectus may sell from time to time. We
will not receive any of the proceeds from these sales. We have agreed to pay the
expenses  incurred in  registering  the shares,  including  legal and accounting
fees.

      The shares have not been registered under the securities laws of any state
or other  jurisdiction  as of the date of this  prospectus.  Brokers  or dealers
should  confirm the existence of an exemption  from  registration  or effectuate
such registration in connection with any offer and sale of the shares.

      This  prospectus  describes  certain risk factors that you should consider
before purchasing the shares. See "Risk Factors" beginning on page 6. You should
read this prospectus  together with the additional  information  described under
the heading "Where You Can Find More Information."

                           FORWARD-LOOKING STATEMENTS

      This prospectus contains or implies certain  "forward-looking  statements"
within the meaning of the Private  Securities  Litigation Reform Act of 1995, as
amended,  including statements regarding the efficacy of potential products, the
timelines for bringing such products to market and the  availability  of funding
sources for continued development of such products.  Forward-looking  statements
are  based on  management's  estimates,  assumptions  and  projections,  and are
subject to  uncertainties,  many of which are beyond the control of SIGA. Actual
results may differ  materially  from those  anticipated  in any  forward-looking
statement.  Factors that may cause such  differences  include the risks that (a)
potential products that appear promising to SIGA or its collaborators  cannot be
shown to be efficacious or safe in subsequent  pre-clinical or clinical  trials,
(b)  SIGA  or  its  collaborators  will  not  obtain  appropriate  or  necessary
governmental approvals to market these or other potential products, (c) SIGA may
not be able to obtain anticipated funding for its development  projects or other
needed  funding,  (d) SIGA may not be able to secure  funding  from  anticipated
government  contracts and grants,  (e) SIGA may not be able to secure or enforce
adequate legal protection,  including patent protection,  for its products,  (f)
unanticipated   internal  control  deficiencies  or  weaknesses  or  ineffective
disclosure  controls  and  procedures  and (g)  regulatory  approval  for SIGA's
products may require  further or  additional  testing that will delay or prevent
approval.  More detailed information about SIGA and risk factors that may affect
the realization of  forward-looking  statements,  including the  forward-looking
statements  in this  presentation,  is set  forth  in  SIGA's  filings  with the
Securities and Exchange Commission,  including SIGA's Annual Report on Form 10-K
for the fiscal year ended  December 31, 2005,  and in other  documents that SIGA
has filed with the Commission. SIGA urges investors and security holders to read
those   documents   free   of   charge   at  the   Commission's   Web   site  at
http://www.sec.gov.  Interested  parties may also obtain those documents free of
charge from SIGA.  Forward-looking statements speak only as of the date they are
made, and except for any obligation under the U.S.  federal  securities laws, we
undertake  no  obligation  to  publicly  update any  forward-looking  statements
whether as a result of new information, future events or otherwise.

      Although we believe that our expectations are reasonable, we cannot assure
you that our  expectations  will prove to be correct.  Should any one or more of
these risks or uncertainties  materialize,  or should any underlying assumptions
prove incorrect, actual results may vary materially from those described in this
prospectus as anticipated, believed, estimated, expected, intended or planned.


                                       14


                                 USE OF PROCEEDS

      The net proceeds  from the sale of the shares of common stock offered will
be received by the selling stockholders. We will not receive any of the proceeds
from the sale of the shares of common stock offered by the selling stockholders.


                                       15


                              SELLING STOCKHOLDERS

      The table below sets forth information  regarding  ownership of our common
stock by the selling  stockholders  as of November 20,  2006,  and the shares of
common stock to be sold by them under this prospectus.  Beneficial  ownership is
determined in accordance  with rules of the Securities  and Exchange  Commission
and includes voting or investment  power with respect to the securities.  Except
as indicated by footnote, and subject to applicable community property laws, the
persons named in the table have sole voting and investment power with respect to
all shares of common stock shown as beneficially owned by them. The rules of the
Securities and Exchange  Commission  require that the number of shares of common
stock  outstanding  used in  calculating  the  percentage for each listed person
includes the shares of common stock underlying  warrants or options held by such
person that are exercisable  within 60 days of November 30, 2006. As of November
30, 2006, 31,909,204 shares of our common stock were outstanding.



                                                                           Securities Owned After
                                   Securities Owned Prior to Offering           Offering (1)

                                                             Shares of     Number of
                                 Shares of    Percent of      Common       Shares of    Percent of
                                  Common        Common     Stock Offered    Common        Common
Name of Selling Stockholder        Stock        Stock         Hereby         Stock        Stock
                                                                            

Bjorn J. Holubar                  125,000        0.39%        125,000         --           0.0%
Cary L. Fields                    375,000        1.18%        375,000         --           0.0%


      The  information  provided in the table above with  respect to the selling
stockholders has been obtained from such selling stockholders.

      The  selling  stockholders  have not within  the past three  years had any
position,  office  or  other  material  relationship  with  us  or  any  of  our
predecessors or affiliates.

      Because  the  selling  stockholders  may sell all or some  portion  of the
shares of common stock  beneficially  owned by them, only an estimate  (assuming
the selling  stockholders sell all of the shares offered hereby) can be given as
to the number of shares of common stock that will be  beneficially  owned by the
selling stockholders after this offering. In addition,  the selling stockholders
may have sold,  transferred or otherwise  disposed of, or may sell,  transfer or
otherwise  dispose of, at any time or from time to time since the dates on which
they provided the information  regarding the shares  beneficially owned by them,
all or a portion of the shares beneficially owned by them in transactions exempt
from the registration requirements of the Securities Act.

      We have filed  with the  Securities  and  Exchange  Commission,  under the
Securities  Act of 1933,  a  registration  statement  on Form S-3, of which this
prospectus  forms a part, with respect to the resale of the securities from time
to time on the NASDAQ Capital Market or in privately-negotiated transactions and
have  agreed  to  prepare  and  file  such  amendments  and  supplements  to the
registration  statement as may be necessary to keep the  registration  statement
effective  until  the  earlier  of (i) five  years  from the date on which  this
registration statement on Form S-3 becomes effective,  or (ii) the date on which
the selling stockholders have sold all of the shares of common stock.

                              PLAN OF DISTRIBUTION

The selling stockholders may, from time to time, sell any or all of their shares
of common stock on any stock exchange,  market or trading  facility on which the
shares  are traded or in private  transactions.  These  sales may be at fixed or
negotiated  prices.  The  selling  stockholders  may  use any one or more of the
following methods when selling shares:

o     ordinary   brokerage   transactions   and   transactions   in  which   the
      broker-dealer solicits purchasers;


                                       16


o     block trades in which the broker-dealer will attempt to sell the shares as
      agent but may  position  and resell a portion of the block as principal to
      facilitate the transaction;

o     purchases by a broker-dealer as principal and resale by the  broker-dealer
      for its account;

o     an exchange  distribution  in accordance  with the rules of the applicable
      exchange;

o     privately negotiated transactions;

o     short sales;

o     broker-dealers may agree with the selling stockholders to sell a specified
      number of such shares at a stipulated price per share;

o     a combination of any such methods of sale; and

o     any other method permitted pursuant to applicable law.

The  selling  stockholders  may  also  sell  shares  under  Rule 144  under  the
Securities Act, if available, rather than under this prospectus.

      The selling  stockholders  may also engage in short sales against the box,
puts and calls and other  transactions  in our  securities or derivatives of our
securities and may sell or deliver shares in connection with these trades.

      Broker-dealers  engaged by the selling  stockholders may arrange for other
brokers-dealers to participate in sales.  Broker-dealers may receive commissions
or discounts from the selling  stockholders  (or, if any  broker-dealer  acts as
agent  for the  purchaser  of  shares,  from the  purchaser)  in  amounts  to be
negotiated.  The  selling  stockholders  do not  expect  these  commissions  and
discounts to exceed what is customary in the types of transactions involved. Any
profits on the  resale of shares of common  stock by a  broker-dealer  acting as
principal might be deemed to be underwriting  discounts or commissions under the
Securities  Act.  Discounts,   concessions,   commissions  and  similar  selling
expenses,  if any, attributable to the sale of shares will be borne by a selling
stockholder.  The selling  stockholders may agree to indemnify any agent, dealer
or broker-dealer that participates in transactions involving sales of the shares
if liabilities are imposed on that person under the Securities Act.

      The selling  stockholders may from time to time pledge or grant a security
interest in some or all of the shares of common stock owned by them and, if they
default in the performance of their secured obligations, the pledgees or secured
parties  may offer and sell the  shares of common  stock from time to time under
this prospectus  after we have filed an amendment to this prospectus  under Rule
424(b)(3) or other  applicable  provision of the Securities Act of 1933 amending
the list of selling  stockholders  to include the pledgee,  transferee  or other
successors in interest as selling stockholders under this prospectus.

      The selling  stockholders  also may transfer the shares of common stock in
other circumstances, in which case the transferees, pledgees or other successors
in  interest  will  be the  selling  beneficial  owners  for  purposes  of  this
prospectus  and may sell the shares of common stock from time to time under this
prospectus  after we have  filed an  amendment  to this  prospectus  under  Rule
424(b)(3) or other  applicable  provision of the Securities Act of 1933 amending
the list of selling  stockholders  to include the pledgee,  transferee  or other
successors in interest as selling stockholders under this prospectus.

      The  selling  stockholders  and any  broker-dealers  or  agents  that  are
involved  in  selling   the  shares  of  common   stock  may  be  deemed  to  be
"underwriters"  within the meaning of the Securities Act in connection with such
sales. In such event, any commissions  received by such broker-dealers or agents
and any profit on the resale of the shares of common stock purchased by them may
be deemed to be underwriting commissions or discounts under the Securities Act.

      We are required to pay all fees and expenses  incident to the registration
of the  shares  of  common  stock.  We have  agreed  to  indemnify  the  selling
stockholders against certain losses, claims, damages and liabilities,  including
liabilities under the Securities Act.

      The selling  stockholders  have advised us that they have not entered into
any  agreements,   understandings  or  arrangements  with  any  underwriters  or
broker-dealers  regarding the sale of their shares of common stock, nor is there
an underwriter or coordinating  broker acting in connection with a proposed sale
of shares of common stock by any selling stockholder.  If we are notified by any
selling  stockholder that any material  arrangement has been entered into with a
broker-dealer for the sale of shares of common


                                       17


stock, if required, we will file a supplement to this prospectus. If the selling
stockholders  use this  prospectus  for any sale of the shares of common  stock,
they will be subject to the prospectus  delivery  requirements of the Securities
Act.

      The anti-manipulation  rules of Regulation M under the Securities Exchange
Act of 1934 may apply to sales of our common stock and activities of the selling
stockholders.

                                  LEGAL MATTERS

      The validity of the shares of common stock  offered  hereby will be passed
upon for us by Kramer  Levin  Naftalis & Frankel  LLP.  Thomas E.  Constance,  a
director of SIGA, is Chairman of Kramer Levin Naftalis & Frankel LLP, a law firm
in New York City, which SIGA has retained to provide legal services.

                                     EXPERTS

      The financial  statements  incorporated in this prospectus by reference to
the Annual Report on Form 10-K for the year ended December 31, 2005 have been so
incorporated  in  reliance  on the  report  of  PricewaterhouseCoopers  LLP,  an
independent  registered  public  accounting firm, given on the authority of said
firm as experts in auditing and accounting.

     COMMISSION'S POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES

      Insofar as  indemnification  for liabilities  arising under the Securities
Act of 1933 may be permitted to our directors, officers and controlling persons,
we have  been  advised  that  in the  opinion  of the  Securities  and  Exchange
Commission  such  indemnification  is against  public policy as expressed in the
Securities Act and is, therefore,  unenforceable.  In the event that a claim for
indemnification  against  such  liabilities  (other  than the  payment  by us of
expenses  incurred  or paid by one of our  directors,  officers  or  controlling
persons in the successful defense of any action, suit or proceeding) is asserted
by  that  director,  officer  or  controlling  person  in  connection  with  the
securities being  registered,  we will, unless in the opinion of our counsel the
matter  has  been  settled  by  controlling  precedent,  submit  to a  court  of
appropriate  jurisdiction  the question  whether that  indemnification  by us is
against public policy as expressed in the Securities Act and will be governed by
the final adjudication of that issue.

                             ADDITIONAL INFORMATION

Government Filings.

      We file annual,  quarterly and special reports, proxy statements and other
information  with the SEC. Our SEC filings are  available to the public over the
Internet at the SEC's web site at http://www.sec.gov. You may also read and copy
any document we file at the SEC's public  reference room at 100 F Street,  N.E.,
Washington, D.C. 20549. You may obtain information on the operation of the SEC's
public reference room in Washington, D.C. by calling the SEC at 1-800-SEC-0330.

      We  have  filed  with  the SEC a  registration  statement  on form  S-3 to
register the shares of common stock to be offered.  This  prospectus  is part of
that  registration  statement  and, as permitted  by the SEC's  rules,  does not
contain all the information included in the registration statement.  For further
information about us and our common stock, you should refer to that registration
statement and to the exhibits and schedules  filed as part of that  registration
statement,  as well as the documents we have incorporated by reference which are
discussed  below.  You can  review  and copy  the  registration  statement,  its
exhibits  and  schedules,  as well as the  documents  we  have  incorporated  by
reference, at the public reference facilities maintained by the SEC as described
above. The  registration  statement,  including its exhibits and schedules,  are
also available on the SEC's web site, given above.


                                       18


Stock Market.

      Shares of our common stock are traded on the NASDAQ Capital Market.

                           INCORPORATION BY REFERENCE

      The SEC allows us to incorporate by reference the information we file with
it, which means that we can disclose  important  information to you by referring
you  to  those  documents.  The  information  incorporated  by  reference  is an
important part of this  prospectus,  and information that we file later with the
SEC will automatically update and supersede this information.  We incorporate by
reference the documents  listed below and any further  filings made with the SEC
under  Sections  13(a),  13(c),  14 or 15(d) of the  Exchange  Act,  until  this
offering has been completed:

      o     the Annual Report on Form 10-K for the year ended December 31, 2005;

      o     the  description of our common stock  contained in our  registration
            statement on Form 8-A under  Section 12 of the Exchange  Act,  dated
            September 5, 1997,  including any amendment or reports filed for the
            purpose of updating such description;

      o     quarterly report on Form 10-Q for the quarter ended March 31, 2006;

      o     quarterly report on Form 10-Q for the quarter ended June 30, 2006;

      o     quarterly  report on Form 10-Q for the quarter  ended  September 30,
            2006; and

      o     amended  quarterly  report  on Form  10-Q/A  for the  quarter  ended
            September 30, 2006;

      o     proxy   statement  on  Schedule  14A  for  the  annual   meeting  of
            stockholders dated December 19, 2006; and

      o     Our current  reports on Form 8-K filed on January 5, 2006,  February
            3, 2006,  February 7, 2006, March 14, 2006, March 22, 2006, April 3,
            2006,  April 20, 2006,  May 4, 2006,  June 13, 2006,  June 20, 2006,
            July 25, 2006, August 28, 2006, September 25, 2006, October 4, 2006,
            October 11, 2006, October 18, 2006,  October 20, 2006,  December 19,
            2006, December 20, 2006, and December 22, 2006.

      We will furnish to any person,  including any  beneficial  owner,  to whom
this  prospectus is delivered,  without  charge,  a copy of these documents upon
written or oral request to Thomas N.  Konatich,  Chief  Financial  Officer,  420
Lexington Avenue, Suite 408, New York, New York 10170, tel. (212) 672-9100.

                                       19